knowledge -WSS

knowledge

author：fashion 2025-09-28 23:56:27 - browse：53

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Eyeing GLP

hotspot

entertainment

WSS

New Covid vaccine is recommended for everyone 6 months or older

Addressing health care workers' trauma can help fight burnout

New weight loss drugs vying to be the next Wegovy or Mounjaro

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

IRA could hurt research into orphan drugs for rare diseases

Food makers tried to stack nutrition panel with preferred experts

hotspot

knowledge

Wikipedia

Cancer drug shortages should be causing more outrage

A common UTI test for kids haunts adults as a traumatic 'nightmare'

How to save PrEP access — and even expand it

Acelyrin, a rare IPO success, stumbles in its first big test

Virginia high school admissions case could be legal follow

Study finds gene variants tied to breast cancer risk in Black women

23andMe had bad news about my health. I wish a person had delivered it

Acelyrin, a rare IPO success, stumbles in its first big test

ChatGPT in medicine: STAT answers readers' burning questions

Liver decline slowed by off

Wikipedia

H5N1 virus can be tracked in retail milk, scientists say

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Food makers tried to stack nutrition panel with preferred experts

New weight loss drugs vying to be the next Wegovy or Mounjaro

Citing H5N1 threat, CDC urges peak flu monitoring this summer

hotspot

entertainment

Wikipedia

hotspot